- About Us
- Reproductive Health & Pregnancy Therapeutics
- Our Pipeline
- News & Events
To date, preterm labor is a condition for which only treatments with limited efficacy or restrictive safety issues are available. This includes the off-label use of tocolytics, which have a limited efficacy in suppressing uterine contractions and delaying birth.
OBE022 is a potential first-in-class, once daily, oral and selective PGF2α receptor antagonist designed to control preterm labor by reducing inflammation, decreasing uterine contractions and preventing cervical changes and membrane ruptures. ObsEva believes this is an innovative approach to controlling preterm labor and delaying birth and OBE022 is being developed as an oral treatment for patients between 24 to 34 weeks of gestation. ObsEva commenced a Phase 1 clinical trial of OBE022 in mid-2016.